Celestoderm-V ointment

Country: Armenía

Tungumál: enska

Heimild: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

Virkt innihaldsefni:

betamethasone (betamethasone 17-valerate)

Fáanlegur frá:

Schering-Plough Labo N.V.

ATC númer:

D07AC01

INN (Alþjóðlegt nafn):

betamethasone (betamethasone 17-valerate)

Skammtar:

1mg/g

Lyfjaform:

ointment

Einingar í pakka:

aluminium tube 30g

Gerð lyfseðils:

Prescription

Leyfisstaða:

Registered

Leyfisdagur:

2019-04-22

Vara einkenni

SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE MEDICINAL PRODUCT
CELESTODERM-V
®
2.
COMPOSITION
1 g of ointment contains
_active substance:_
1 mg betamethasone (as betamethasone 17-valerate 1.22 mg);
_excipients:_
paraffin white liquid, mineral oil.
3.
PHARMACEUTICAL FORM
Ointment.
_DESCRIPTION: _
soft white homogenous ointment, without foreign matters.
PHARMACOTHERAPEUTIC GROUP
Corticosteroids for dermatological use. Corticosteroids, potent (group
III).
АТС Code D07A C01.
4.1 THERAPEUTIC INDICATIONS
Relief of the inflammatory manifestations of corticosteroid-responsive
dermatoses such as:
eczema (atopic, nummular), contact dermatitis, seborrheic dermatitis,
neurodermatitis, solar
dermatitis, exfoliative dermatitis, dermatitis due to radiation,
intertrigo, psoriasis (excluding
disseminated psoriasis).
4.2. DOSAGE AND ADMINISTRATION
A thin film of Celestoderm-V
®
should be applied to the affected area 1-3 times daily depending
on severity of the condition. Application once or twice a day is often
feasible and effective.
Frequency of application should be determined according to severity of
the condition. While mild
cases may respond to once a day application, more severe cases may
require more frequent
application.
Do not apply under occlusive dressings as it can potentiate adverse
actions of medication.
Continuous use of the medication should not exceed 4 weeks. After
therapeutic effect is achieved
frequency of Celestoderm-V
®
should be decreased or less active topical corticosteroid should be
used, and supportive therapy should be continued with gradual
withdrawal of the medication.
If clinical improvement is not achieved by two to four weeks,
examination should be repeated,
and treatment should be reviewed.
4.3 CONTRAINDICATIONS
Untreated skin diseases induced by bacterial infections of the skin
(e.g. pyogenic dermatitis,
tuberculosis and syphilitic processes), viral infections of the skin
(e.g. varicella, herpes simplex,
herpes zoster, verrucas vulga, warts, molluscum contagiosum), fungal
infections o